双等离子分子吸附系统在区域酸盐抗凝剂期间不同治疗剂量的有效性和安全性:试点研究
Xiankun Sun1, Yuan Zhao1, Mingjin Dai1
1Department of Nephrology and Kidney Research Institute, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Journal of clinical apheresis
|April 10, 2025
概括
增加双重血分子吸附系统 (DPMAS) 与区域酸盐抗凝剂 (RCA) 的剂量,改善了肝衰竭患者的胆红素清除. 然而,高剂量增加了凝血风险,需要仔细考虑治疗强度.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 关键护理医学 关键护理医学
- 生物医学工程 生物医学工程
背景情况:
- 肝衰竭需要有效的解毒方法.
- 双等离子体分子吸附系统 (DPMAS) 用于肝脏支持.
- 在DPMAS治疗期间使用区域酸盐抗凝剂 (RCA).
研究的目的:
- 评估肝衰竭患者在RCA期间升级DPMAS剂量的安全性和有效性.
- 确定不同DPMAS治疗量对临床结果和实验室参数的影响.
- 评估并发症的发生率,包括与抗凝血相关的不良事件和凝血事件.
主要方法:
- 一项前性非随机对照试验,涉及303名肝衰竭患者.
- 患者被分为三组,在RCA.下接受3L,4.5L或6L的DPMAS治疗.
- 关键的实验室指标,安全参数和凝血事件被监测和在各组进行了比较.
主要成果:
- 在两组之间观察到胆红素清除率的显著差异 (p < 0.001),6L组的清除率高于3L组 (p < 0.001).
- 大多数实验室指标或低血压,低血症,酸性,性,高血症,高乳糖血症和过敏反应的发病率在两组之间没有显著差异 (p > 0.05).
- 在6L组与3L组相比,在统计学上显著增加了凝血事件 (p = 0.011).
结论:
- 在RCA-DPMAS治疗中增加治疗性血体积可以增强肝衰竭中胆红素的去除.
- 较高的DPMAS剂量不会显著增加酸盐抗凝相关的并发症.
- 凝血事件的风险是对升级RCA-DPMAS剂量的担忧,需要谨慎管理.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
568
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
568
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
417
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
417
Depolarizing Blockers: Pharmocokinetics
296
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
296
Local Anesthetics: Clinical Application as Intravenous Regional Anesthesia
330
Intravenous regional anesthesia or the Bier block technique is used to anesthetize a specific limb or extremity. It uses exsanguinated or blood-drained vessels to transport local anesthetics or LAs to the peripheral nerve trunks. Lidocaine without vasoconstrictors like epinephrine is most commonly used for this technique. Other drugs used are prilocaine, ropivacaine, and chloroprocaine. Bupivacaine is not recommended for this technique due to its high cardiac toxicity.
One of the advantages of...
One of the advantages of...
330


